Markets

Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders

Oct 1, 2026 · 04:02 PM ET· updated 7h ago

Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102

Why It Matters

Arvinas will show early test results from a new Parkinson's medicine. When companies share positive early data, it often means the drug might work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ARVN7.50

-0.24 (-3.04%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.